Special Thanks to Our 2021 Collaborating Partner
Thank you to our 2021 Education Partners
Presenting Education Partner
Takeda’s Commitment to Gastroenterology in the United States: Takeda sees an urgent need for improving patient care in gastroenterology (GI) and has focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for more than 25 years. We push boundaries and work across modalities, taking on the most complex GI conditions and the most neglected patient needs, boldly advancing original thinking and creatively tackling barriers to make a meaningful difference for patients. Challenging expectations and enabling innovative thinking, Takeda is part of more than 200 collaborations connecting people with a mutual commitment to action. Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, short bowel syndrome, and motility and esophageal disorders. Our GI Research & Development team is also exploring solutions in immune-related diseases, motility and liver diseases.
Diamond Education Partner
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, neurology, immunology, and oncology. It helps people with debilitating and complex conditions that are often difficult to diagnose and treat, and is dedicated to discovering and advancing new therapies, providing hope to patients and their families worldwide. Sanofi Genzyme’s ambition is to be the industry leader in specialty care. Its approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Platinum Education Partners
Allakos is a biotech company developing targeted therapies for inflammatory diseases with significant unmet medical needs. We strive to understand patient needs and are committed to collaborating with advocacy groups and physicians to incorporate their perspectives into our programs. Our focus is on eosinophilic gastrointestinal diseases (EGIDs), a group of chronic inflammatory diseases characterized by persistent gastrointestinal symptoms and elevated mast cells and eosinophils in the esophagus (EoE), stomach (EG), and/or duodenum (EoD).
Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key area of focus for the Company. AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas. The Company’s growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including systemic eosinophilic-driven diseases, gastroenterology, rheumatology, and dermatology. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
As your lifelong nutrition partner and advocate, we invite you to visit us at our EleCare booth to learn more about elemental nutrition or talk with one of our specialists about how to access EleCare. Visit EleCare.com for additional product and usage information.
Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company aiming to advance treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition. The company was established in 2020 to accelerate clinical development of EoE therapies and build on the work initiated by Adare Pharmaceuticals, particularly APT-1011, which is currently in a Phase 3 clinical trial. Despite growing awareness of EoE and its underserved patient population, no FDA approved treatment exists for the disease today. Ellodi Pharmaceuticals has assembled a seasoned team with deep expertise in developing and commercializing innovative therapies for gastrointestinal disorders and rare diseases. With patients and caregivers at the center of every decision we make, we are focused on developing and delivering innovative therapies that can meaningfully improve and transform the lives of patients with EoE.
For over a century, Mead Johnson Nutrition has combined state-of-the-art research, scientific partnerships, and commitment to the highest quality and nutritional standards to deliver meaningful innovations to our consumers. Millions of parents and healthcare professionals around the world trust our products to nourish babies for their best start in life. To explore our Enfamil portfolio of tailored nutrition, visit www.hcp.meadjohnson.com and visit our booth to learn more about PurAmino.
Gold Education Partners
Silver Education Partners
Cambrooke
EveryLife Foundation for Rare Diseases
Pharmaceutical Research and Manufacturers of America (PhRMA)
For more information about EOS Connection 2021, please visit the following pages or contact us at conference@apfed.org.